Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The closing price of C4 Therapeutics Inc (NASDAQ: CCCC) was $6.86 for the day, up 2.08% from the previous closing price of $6.72. In other words, the price has increased by $2.08 from its previous closing price. On the day, 0.75 million shares were traded. CCCC stock price reached its highest trading level at $6.9988 during the session, while it also had its lowest trading level at $6.705.
Ratios:
Our analysis of CCCC’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 6.34 and its Current Ratio is at 6.34. In the meantime, Its Debt-to-Equity ratio is 0.29 whereas as Long-Term Debt/Eq ratio is at 0.27.
On December 13, 2023, Stifel Upgraded its rating to Buy which previously was Hold and also upped its target price recommendation from $2 to $12.
Credit Suisse Upgraded its Underperform to Neutral on February 24, 2023, whereas the target price for the stock was revised from $12 to $10.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CCCC now has a Market Capitalization of 470600832 and an Enterprise Value of 278291488. For the stock, the TTM Price-to-Sale (P/S) ratio is 22.67 while its Price-to-Book (P/B) ratio in mrq is 1.69. Its current Enterprise Value per Revenue stands at 13.408 whereas that against EBITDA is -2.029.
Stock Price History:
Over the past 52 weeks, CCCC has reached a high of $11.88, while it has fallen to a 52-week low of $1.06. The 50-Day Moving Average of the stock is -19.12%, while the 200-Day Moving Average is calculated to be 50.10%.
Shares Statistics:
CCCC traded an average of 2.70M shares per day over the past three months and 1328520 shares per day over the past ten days. A total of 60.47M shares are outstanding, with a floating share count of 57.71M. Insiders hold about 15.88% of the company’s shares, while institutions hold 71.91% stake in the company. Shares short for CCCC as of 1711584000 were 9149358 with a Short Ratio of 3.38, compared to 1709164800 on 2966611. Therefore, it implies a Short% of Shares Outstanding of 9149358 and a Short% of Float of 18.92.
Earnings Estimates
The market rating of C4 Therapeutics Inc (CCCC) is currently shaped by the ongoing analysis conducted by C4 Therapeutics, Inc. analysts closely monitoring its performance.The consensus estimate for the next quarter is $25.57, with high estimates of $519.18 and low estimates of $11.40.
